ࡱ> WYVq`Z(bjbjqPqP .*::K     2  BT2J XXX|WWWSSSSSSS$tUhWpS9WWSX|Smmm X|SmSmmIDJX$> :ç cJ&ST0BTJ&LXGLXLJJLXOWhmQTzWWWSSc WWWBT        $  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20456453" \l "#" \o "Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases." Clin Microbiol Infect. 2011 Mar;17(3):371-9. doi: 10.1111/j.1469-0691.2010.03256.x. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nagy%20E%22%5BAuthor%5D" Nagy E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Urb%C3%A1n%20E%22%5BAuthor%5D" Urbn E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nord%20CE%22%5BAuthor%5D" Nord CE;  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22ESCMID%20Study%20Group%20on%20Antimicrobial%20Resistance%20in%20Anaerobic%20Bacteria%22%5BCorporate%20Author%5D" ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20456453" \l "#" \o "Open/close investigator list" Collaborators (22)  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pi%C3%A9rard%20D%22" Pirard D,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Glupczynski%20Y%22" Glupczynski Y,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nonhoff%20C%22" Nonhoff C,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ieven%20M%22" Ieven M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kalenic%20S%22" Kalenic S,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chmelarova%20E%22" Chmelarova E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22K%C3%B6n%C3%B6nen%20E%22" Knnen E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Calvet%20L%22" Calvet L,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dubreuil%20L%22" Dubreuil L,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22D%C3%B3sa%20E%22" Dsa E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Papaparaskevas%20J%22" Papaparaskevas J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Szikra%20L%22" Szikra L,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Miszti%20C%22" Miszti C,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Terhes%20G%22" Terhes G,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mazzariol%20A%22" Mazzariol A,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vila%20J%22" Vila J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hedberg%20M%22" Hedberg M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Degener%20J%22" Degener J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wildeboer-Veloo%20L%22" Wildeboer-Veloo L,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22G%C3%BCrler%20N%22" Grler N,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22G%C3%BCrler%20S%22" Grler S,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ulger%20N%22" Ulger N. Source Institute of Clinical Microbiology, Albert Szent-Gyrgyi Medical Centre, University of Szeged, Hungary. agye@mlab.szote.u-szeged.hu Abstract The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13 countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated according to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The present data were compared with those obtained 10 and 20 years ago at a European level. High-level resistance (MIC e" 64 mg/L) to ampicillin was observed in 44.5% of the strains, which is a significant increase relative to 20 years ago (16%). Piperacillin/tazobactam was more active than amoxicillin/clavulanic acid (3.1% and 10.4% resistance, respectively), again with a resistance increase relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.2%, 32.4% and 13.6%, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2%, <1% and 1.7%). Nonsusceptible strains to imipenem and metronidazole were more resistant to other anti-anaerobic drugs. Differences were detected between geographical areas, with higher resistance rates for moxifloxacin in Scandinavian countries (21.4%) than in Mediterranean countries (5.4%), whereas, for clindamycin, the resistance rates were higher in Mediterranean (41.8%) and lower in Scandinavian countries (22.5%). Piperacillin/tazobactam resistance was also higher in Scandinavian countries. 2010 The Authors. Journal Compilation 2010 European Society of Clinical Microbiology and Infectious Diseases. PMID: 20456453 [PubMed - indexed for MEDLINE] Full Text Sources  % > ? F G I J O P    \ ] f g i j     ߯*hJ@0J>*B*CJOJQJ^JaJphhJ@CJOJQJ^JaJ#jhJ@CJOJQJU^JaJhJ@CJOJQJ^JaJhJ@0JCJOJQJ^JaJhJ@CJOJQJ^JaJ#jhJ@CJOJQJU^JaJ6%  !<Y(Z(x-D@&M gdJ@d-DM ^gdJ@d-DM gdJ@ -DM gdJ@d-DM gdJ@ -DM gdJ@d-DM gdJ@Z(   a b i j l m  noxy{|"#%&opvwyz#$,-/0vw +,.*hJ@0J>*B*CJOJQJ^JaJphhJ@0JCJOJQJ^JaJ#jhJ@CJOJQJU^JaJhJ@CJOJQJ^JaJI./stz{}~$%'(wx019:<=!(V(X(Y(Z(߬ߪߦh*U)hJ@5B*CJOJQJ\^JaJphhJ@CJOJQJ^JaJhJ@0JCJOJQJ^JaJhJ@CJOJQJ^JaJ#jhJ@CJOJQJU^JaJ6HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20456453" \l "#" \o "Show/hide content"  ,1h. A!"#$% @@@ NormalCJ_HaJmH sH tH``` J@ Heading 1ddd@&[$\$5CJ$KH$\aJ$mHsHV`"V J@ Heading 2dd@&[$\$5CJ+\aJ+mHsHV`2V J@ Heading 3dd@&[$\$5CJ"\aJ"mHsHV`BV J@ Heading 4dd@&[$\$5CJ\aJmHsHDA@D Default Paragraph FontRiR  Table Normal4 l4a (k(No List4U`4 J@ Hyperlink >*ph.X`. J@Emphasis6]J^`J J@ Normal (Web)dd[$\$mHsH&o!& J@invert1No1N J@ui-ncbitoggler-master-text2oB J@Cui-ncbi-toggler-slave ui-widget ui-ncbitoggler ui-ncbitoggler-slavedd[$\$mHsH*oQ* J@ highlight&oa& J@source2$oq$ J@numberPoP J@hton1x ^xB* CJaJmHph7lsHK*!"&!"&<Kr%  ! <JMp#/p#p#/p#/p#jp#/p#/p#/p#/p#/p#/p#/p#/p#jp#/p#%  ! <JM000%(0%0(0%0  0%0 0000H000%  ! <JM@K0K0K0K0K0K0cK0cK0cK0cK0cK0K0K0@ 0> .Z(Z(Z(>FIO \fiail nx{"%ovy#,/v + . s z }  $ ' w 0 9 < GHKXXXXXXXXXXXXXXXXXXXXXXXXXXXXX(8@0(  B S  ? lm+nl+o,,p,q,-r-s,.t.u,/ -A=eM  <#UDkM * isiresearchsoft-com/cwywcitation n %23AEPQY`hw|?D]dbg ov pt$*w} )  " x 1 7         ! $ % 5 = H I Q X ` a h n y z ~       " # , - 6 : A F R S X Y \ f i j r s | !",@JKNOWdghoqv| "%*+/2<=EFNRYZackluy  !#05@Wefmqy~  "&23<EIMZ[dmtvyz $01:CFGNPWXckst{M%]   ! ;<M:::%MMV(( ~zLy0&E2^No44”|8޽h9tvNcM&oz& {V̕?TZ< _ c H^O$m HLo,"ksRUxF$o|xu^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(o^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(  ^ `CJOJQJo(^`CJOJQJo(!!^!`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(o4?TZLy8"ks {V2o|cMh9O$mLo cRUx( QF<+}-\+z7;g|c?,s5lUaJlqm "=LF<+-;DpE'Zsd>}(* Hd>`ThT\XThTjm }";#ThTL)#VOz~i(F<+_(}}(*^AG6*ThTF<+7;gJ[,"=Lm>-1'q.ThTL$bd0}(*$3.\5;DpRg6. 8`9c9FC?|X:+z<::j&_` 6=`%=z~i(`:>|c?|c?ThTFC?5x@EA},C"=L)QD;Dp Dwx,E";#^AG$3%IaJ"=L~9J\5"K,y"=L)QD3}FO:>VOX!O%IQ7R8x&S.@+|VRg6#Y}(*j&_F<+wYWf"=L %g}4" hFC??kbd0`|.l DRRl"=Lpl}5l!OHn)QDq7o)QD;Dp|X:1'q";#Ir %gZs}vThTF>x <`5xXwx}8x,E.h,yQ7R`,y}+z!O.@+|"Kkz  mH]^}Os=>GZ.YN{oGtTBBfx: $^=&'&' (*u+E;,--.b.~y./ 2r$2V2i 30E3d4G89 9";e;e<T?:AJBCCTCEYFgF3HI1I#L)M3M7DPKP[PR8RaR/SyS,RTkTnT.UZZpZ[4[W[jV^Q_V'_X_M`~bxd,HeZf?f Vg7\g)h2h)iti&kzkmCmmooprsr9tUtvyDxz{0}NH}d}$~dV~H )* R:1I^a#./}v8$;;L7Rnrg!:GR^m-AS%Yzi$U^Z*_EOU^A ?\8^!W\M2V6@ lH'A2R\ V6A"QZ8TS @z@yyy!,taht`0 G nEfp2cwwd*4>t d% Q/HgzF$- [%GK` AR J@r~ 0*X%Z+&K|"~S|FNGJw@JJ.JJ4K@@@@0@@P@UnknownGz Times New Roman5Symbol3& z Arial?5 z Courier New;Wingdings"q`aj #j #I24BB 3HX)?J@Clin Microbiol InfectBudimirBudimirL           Oh+'0|  8 D P\dltClin Microbiol InfectBudimirNormalBudimir1Microsoft Office Word@F#@btç@&&çj՜.+,D՜.+,@ hp|  # B Clin Microbiol Infect Titlel 8@ _PID_HLINKSA$5T,http://www.ncbi.nlm.nih.gov/pubmed/20456453# 7Q8http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ulger%20N%22JN>http://www.ncbi.nlm.nih.gov/pubmed?term=%22G%C3%BCrler%20S%22J K>http://www.ncbi.nlm.nih.gov/pubmed?term=%22G%C3%BCrler%20N%22CHBhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Wildeboer-Veloo%20L%22LLE:http://www.ncbi.nlm.nih.gov/pubmed?term=%22Degener%20J%22\ZB:http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hedberg%20M%22{!?7http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vila%20J%22/+<<http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mazzariol%20A%22X99http://www.ncbi.nlm.nih.gov/pubmed?term=%22Terhes%20G%22Q69http://www.ncbi.nlm.nih.gov/pubmed?term=%22Miszti%20C%22S39http://www.ncbi.nlm.nih.gov/pubmed?term=%22Szikra%20L%22N0Ahttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Papaparaskevas%20J%22.,-<http://www.ncbi.nlm.nih.gov/pubmed?term=%22D%C3%B3sa%20E%22k1*;http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dubreuil%20L%22Q'9http://www.ncbi.nlm.nih.gov/pubmed?term=%22Calvet%20L%22&3$Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22K%C3%B6n%C3%B6nen%20E%22]!=http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chmelarova%20E%22D@:http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kalenic%20S%22)%8http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ieven%20M%22HS:http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nonhoff%20C%22JR>http://www.ncbi.nlm.nih.gov/pubmed?term=%22Glupczynski%20Y%22n<?http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pi%C3%A9rard%20D%225,http://www.ncbi.nlm.nih.gov/pubmed/20456453#&o http://www.ncbi.nlm.nih.gov/pubmed?term=%22ESCMID%20Study%20Group%20on%20Antimicrobial%20Resistance%20in%20Anaerobic%20Bacteria%22%5BCorporate%20Author%5D>z Dhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Nord%20CE%22%5BAuthor%5D UIhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Urb%C3%A1n%20E%22%5BAuthor%5Dy<Chttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Nagy%20E%22%5BAuthor%5D5,http://www.ncbi.nlm.nih.gov/pubmed/20456453#  !"#$%&'()*+,-./0123456789:;<=>?@ABDEFGHIJLMNOPQRSTUXRoot Entry FFçZ1TableXWordDocument.*SummaryInformation(CDocumentSummaryInformation8KCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q